Drug reference

Ixekizumab

Monoclonal Antibody · Immunomodulator, Antipsoriatic

Monoclonal AntibodyImmunomodulator, Antipsoriatic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Ixekizumab is a human IgG4-κ monoclonal antibody that binds to the IL-17A cytokine and IL17A/F heterodimers. This binding inhibits the activity of interleukin-17A, a key cytokine involved in the pathogenesis of psoriasis and psoriatic arthritis.

Indications

Moderate to severe plaque psoriasis in adultsPsoriatic arthritis (PsA) in adultsRadiographic axial spondyloarthritisadults with active psoriatic arthritisactive ankylosing spondylitisactive nonradiographic axial spondyloarthritis with objective signs of inflammation

Dosing

Adult: Psoriasis: Loading dose of 160 mg subcutaneously followed by 80 mg every 2 weeks to week 12, then 80 mg every 4 weeks. Psoriatic Arthritis: 160 mg subcutaneously at week 0, followed by 80 mg every 4 weeks.

Pharmacokinetics

Peak effect

4 days

Half-life

13 days

Contraindications

Active tuberculosis
Inflammatory bowel disease (may cause or exacerbate)

Side effects

Common

Infection (especially upper respiratory tract infections)

Serious

Activation/exacerbation of tuberculosis
Inflammatory bowel disease (new onset or exacerbation)
increased risk of serious infections
increased risk of inflammatory bowel disease (ibd), including crohn’s disease and ulcerative colitis